Genentech posts long-term data on near-approval Soliris rival

Genentech has shared longer-term phase 3 safety data on its anti-IL-6 antibody satralizumab, adding to the evidence in support of the drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.